148 related articles for article (PubMed ID: 2580625)
1. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung NK; Saarinen UM; Neely JE; Landmeier B; Donovan D; Coccia PF
Cancer Res; 1985 Jun; 45(6):2642-9. PubMed ID: 2580625
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a monoclonal antibody reactive with a glycolipid antigen expressed by tumorigenic and certain immortalized, non-tumorigenic rat esophageal epithelial cell lines.
Wan X; Jamasbi RJ; Stoner GD
Cancer Immunol Immunother; 1993; 36(2):94-100. PubMed ID: 8425214
[TBL] [Abstract][Full Text] [Related]
3. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells.
Czuczman MS; Garin-Chesa P; Lemoli RM; Scheinberg DA
Cancer Immunol Immunother; 1993 Jun; 36(6):387-96. PubMed ID: 8500111
[TBL] [Abstract][Full Text] [Related]
4. Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.
Feyles V; Dixon WT; Sikora LK; McGarry RC; Jerry LM
Cancer Immunol Immunother; 1991; 32(5):261-72. PubMed ID: 1847843
[TBL] [Abstract][Full Text] [Related]
5. Epitope masking of rat esophageal carcinoma tumor-associated antigen by certain coexisting glycolipid and phospholipid molecules: a potential mechanism for tumor cell escape from the host immune responses.
Jamasbi RJ; Wan X; Stoner GD
Cancer Immunol Immunother; 1994 Feb; 38(2):99-106. PubMed ID: 7508339
[TBL] [Abstract][Full Text] [Related]
6. Expression of markers shared between human natural killer cells and neuroblastoma lines.
McGarry RC; Pinto A; Hammersley-Straw DR; Trevenen CL
Cancer Immunol Immunother; 1988; 27(1):47-52. PubMed ID: 2456146
[TBL] [Abstract][Full Text] [Related]
7. Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells.
Shi LR; Eichelbauer D; Borchard F; Jürgens H; Göbel U; Schneider EM
Cancer Immunol Immunother; 1994 Mar; 38(3):208-13. PubMed ID: 8124690
[TBL] [Abstract][Full Text] [Related]
8. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz G; Cheresh DA; Varki NM; Yu A; Staffileno LK; Reisfeld RA
Cancer Res; 1984 Dec; 44(12 Pt 1):5914-20. PubMed ID: 6498849
[TBL] [Abstract][Full Text] [Related]
9. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
Cheung NK; Lazarus H; Miraldi FD; Abramowsky CR; Kallick S; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF; Berger NA
J Clin Oncol; 1987 Sep; 5(9):1430-40. PubMed ID: 3625258
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
11. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
12. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Mora J; Climent A; Roldán M; Flores MC; Varo A; Perez-Jaume S; Jou C; Celma MS; Lazaro JJ; Cheung I; Castañeda A; Gorostegui M; Rodriguez E; Chamorro S; Muñoz JP; Cheung NK
Front Oncol; 2024; 14():1380917. PubMed ID: 38812778
[TBL] [Abstract][Full Text] [Related]
13. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
[TBL] [Abstract][Full Text] [Related]
14. GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J; Shevchenko J; Sennikov S
Front Immunol; 2024; 15():1371345. PubMed ID: 38558810
[TBL] [Abstract][Full Text] [Related]
15. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
16. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
[TBL] [Abstract][Full Text] [Related]
17. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer.
Grover P; Nunez-Cruz S; Leferovich J; Wentz T; Bagchi A; Milone MC; Greene MI
Biochem Biophys Res Commun; 2023 Nov; 680():51-60. PubMed ID: 37717341
[TBL] [Abstract][Full Text] [Related]
18. Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2.
Larrosa C; Mora J; Cheung NK
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509390
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.
Matsumoto Y; Ju T
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509200
[TBL] [Abstract][Full Text] [Related]
20. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
